Merck
Executive Summary
This appears to be Merck & Co., Inc. (MSD), the major US pharmaceutical company headquartered in Rahway, NJ, not a Chinese entity. As a leading global pharma with strong oncology, vaccines, and infectious disease portfolios, Merck maintains an active BD posture for both in-licensing and partnerships. BIOSECURE risk is minimal as this is a US-domiciled company, though they may have manufacturing or research operations in China that require monitoring.
Structure: As a US-incorporated multinational pharmaceutical company, Merck operates through traditional subsidiary structures rather than VIE arrangements. The corporate structure is straightforward for due diligence purposes, with clear ownership chains and regulatory oversight under US securities laws.
Ownership & Shareholder Structure
BIOSECURE Risk
US-domiciled pharmaceutical company with clear BIOSECURE status, though may have supply chain or research collaborations in China
Key Exposures:
- •Potential Chinese manufacturing partners
- •Research collaborations with Chinese institutions
- •Supply chain dependencies
Mitigation: As a US company, primary focus would be on ensuring Chinese partnerships and suppliers comply with BIOSECURE requirements
BD Intelligence
Therapeutic Areas:
Recent Deals: Insufficient data available on recent deal activity
Approach: Standard pharmaceutical BD approach - direct engagement through BD team or scientific partnerships
Red Flags
- ⚠Entity classification as Chinese company appears incorrect
- ⚠Limited corporate intelligence data available
- ⚠Potential data quality issues in source information
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 5
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.